You are here

Enrollment in Clinical Studies for Angiogenic Gene Therapy Candidate Stopped

BERLIN -- January 30, 2004 -- Schering AG Germany (FSE: SCH, NYSE: SHR) announced today that it has stopped enrollment in its Phase IIB/III clinical studies for Ad5FGF-4, its investigational, non-surgical angiogenic gene therapy product being developed for the treatment of patients with stable exertional angina due to coronary artery disease.

The company’s analysis of the interim data of one of the studies has led it to conclude that the studies, as currently designed, will not provide sufficient evidence of efficacy to warrant continued enrollment. The company is instructing investigators to stop patient enrollment. All patients who have already been treated will continue to be evaluated.

Each study is being monitored by an independent Data Safety Monitoring Board (DSMB). No evidence of important safety concerns was found.

Schering AG continues to evaluate and explore the potential of this highly innovative technology.

Source: Schering AG

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens